Recent Pfizer Press Releases

  • 9/5/07 11:30 pm EDT

    Phase II Preliminary Data for Sunitinib Presented at the 12th World Conference on Lung Cancer

    SEOUL, Korea--(BUSINESS WIRE)--Pfizer announced today the initiation of a large, global Phase III clinical trial to evaluate the efficacy and safety of sunitinib malate, in combination with erlotinib, in previously treated patients with advanced non-small cell lung cancer (NSCLC). In addition, preliminary results from a Phase II study, presented this week at the International Association for the Study of Lung Cancer (IASLC) World Conference in Seoul,more...
  • 9/5/07 11:28 am EDT

    Pfizer Announces Key Partnerships with Leading International and Local Organizations to Benefit Patients in Kenya, Ghana and Senegal

    NAIROBI--(BUSINESS WIRE)--To help address critical gaps in malaria treatment and education, Pfizer today announced the launch of Mobilize Against Malaria. This three-country initiative comprising Kenya, Ghana and Senegal will be implemented over the course of five years (2007-2011). Pfizer has selected key international and local health experts to develop and implement public health interventions that engage and educate treatment providers and patientsmore...
  • 9/5/07 11:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer Jeffrey B. Kindler at the 20th Annual Bear Stearns Health Care Conference on Monday, September 10th at 1:30p.m. Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at www.pfizer.com and click on the “the 20thmore...
  • 9/5/07 2:03 am EDT
    VIENNA, Austria--(BUSINESS WIRE)--An observational study of a large United Kingdom primary care database showed that switching patients from Pfizer’s Lipitor® (atorvastatin calcium) Tablets to simvastatin was associated with a 30 percent increase in the relative risk of major cardiovascular events, including heart attacks, strokes and certain types of heart surgeries, or death compared to patients who remained on Lipitor therapymore...
  • 8/27/07 7:30 am EDT

    Companies Will Jointly Conduct Phase III Development and Commercialization of DGAT-1 Inhibitor Compounds

    NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Bristol-Myers Squibb Company (NYSE:BMY) (“companies”) today announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007. Pfizer’s DGAT-1 discovery program includes advanced pre-clinical compounds with potential applications for themore...
  • 8/22/07 9:00 am EDT

    Brings Extensive Operating and Financial Experience in Global Companies Undergoing Rapid Change

    NEW YORK--(BUSINESS WIRE)--Pfizer today announced that Frank A. D’Amelio, a senior executive with almost three decades of extensive operating and financial experience at AT&T, Lucent Technologies and Alcatel-Lucent, including serving as both chief operating officer and chief financial officer at Lucent, will become Pfizer’s Senior Vice President and Chief Financial Officer effective in mid-September. Mr. D’Amelio, who ismore...
  • 8/6/07 1:00 pm EDT

    First in a New Class of Oral HIV Medicines in More Than a Decade

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has approved SelzentryTM (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years. Selzentry blocks viral entry into white blood cells, significantly reducing viral load and increasing T-cell counts in treatment-experienced patients infected with a specific type of HIV. “There is a profound need for newmore...
  • 8/2/07 7:01 pm EDT
    PARIS--(BUSINESS WIRE)--Guidelines from the 2007 St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, published today in the Annals of Oncology (http://annonc.oxfordjournals.org), confirm the value of switching from tamoxifen to an aromatase inhibitor (AI), such as exemestane, for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.i Approximately 360,000 women inmore...
  • 7/30/07 12:01 pm EDT

    In Time for the August Travel Rush, CereniaTM (maropitant citrate) Helps Dogs Come Along for the Ride

    NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health, a business of Pfizer Inc (NYSE: PFE), announced today that Cerenia™ (maropitant citrate), the first and only FDA-approved medication for the prevention and treatment of canine vomiting from a wide range of causes, including motion sickness, is now available by prescription in the United States. Vomiting is one of the most common reasons owners take their dogs to the veterinarian. Accordingmore...
  • 7/25/07 7:04 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a Spanish court has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor. The Commercial Court of First Instance Number 4 in Barcelona, which issued the ruling, found a second patent covering a stabilized formulation that includes atorvastatin is invalid. The patents were challenged by generic manufacturer Ranbaxy.more...